Sirio Pharma sets USP reference standard for ubidecarenone chewable gels

Photo © AdobeStock.com/Tania

Sirio Pharma has announced that its Ubidecarenone Chewable Gels have been added to the United States Pharmacopoeia (USP) monograph. The addition is the result of three years of working with USP to establish required candidate documentary and reference standards that will act as a benchmark against which all future products will be validated. USP reference standards are widely used by regulatory bodies, industries, and third-party labs across 150 countries to assess nutraceutical specifications such as identity, potency, quality, and purity. This marks the first time Sirio Pharma has established a dietary supplement standard with USP, but the company has been involved in formulating 35 global standards.

“We are delighted to be recognized in a certificate of appreciation from the USP for setting the nutra quality standard for chewable ubidecarenone gels, as well as for our contribution to global public health through advancing the safety of medicines and foods,” said Youyou Zhao, head of Global R&D Center for Sirio Pharma, in a press release. “This is a significant milestone in its own right, but also, an example of our company-wide ethos to push the boundaries of formulation science, quality and innovation. We believe in rigorous testing – for organoleptic properties, shelf-life and efficacy – and in driving evidence-based nutrition on every product we develop for our global customers.”